NBIX
Neutral signalScored 2026-09-13 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Neurocrine Biosciences, Inc.
- Nom
- Neurocrine Biosciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $14.5B
- Employés
- 2,500
- PDG
- Kyle W. Gano
- Site web
- https://www.neurocrine.com
- Marché
- ACADAXSMBHVNGHRSHLBBFJAZZ
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 1 250 titres (~227 507,50 $ US)
- Insiders
- Norwalk Leslie V
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,053,873
Avg sell (VWAP, 90d window) $161.12 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,053,873 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-07-28
- Last synced
-
2026-10-19 22:02:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | ABERNETHY MATT | Sell · S · 10b5-1 | 2,311 | $157.20 | $363,285 | Form 4 |
| 2026-09-14 | Boyer David W. | Sell · S · 10b5-1 | 826 | $157.45 | $130,051 | Form 4 |
| 2026-09-09 | BENEVICH ERIC | Sell · S · 10b5-1 | 2,154 | $154.61 | $333,030 | Form 4 |
| 2026-07-28 | Norwalk Leslie V | Sell · S · 10b5-1 | 1,250 | $182.01 | $227,508 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-06-17 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-11-19 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-08-26 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2023-10-27 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-10-27 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-08-14 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-08-14 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-05-02 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-02 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2021-12-21 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2021-12-14 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2021-03-09 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2021-03-09 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2020-12-21 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-11-12 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2020-07-21 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2018-12-13 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-13 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
NBIX combines exceptional financial health (liquidity score 90, fundamentals trend 85) with a strong earnings catalyst (score 75, confidence 0.80), driven by a significant Q2 2026 EPS beat (+26% vs.
The first sentence of the analysis written for NBIX on 2026-09-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $228K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $228K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 3.39 · operating margin 22%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | |
| Ebit Margin | 22.3% | 26.0% | 20.9% | 14.8% | 11.2% | |
| Ebitda Margin | 23.3% | 27.2% | 22.0% | 15.9% | 12.2% | |
| Operating Profit Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | |
| Pretax Profit Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | |
| Continuous Operations Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | |
| Net Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | |
| Bottom Line Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | |
| Current Ratio | 3.393 | 3.397 | 2.454 | 2.703 | 3.958 | |
| Quick Ratio | 3.301 | 3.284 | 2.396 | 2.638 | 3.834 | |
| Solvency Ratio | 0.369 | 0.326 | 0.266 | 0.257 | 0.144 | |
| Cash Ratio | 0.959 | 0.459 | 0.383 | 0.489 | 1.386 | |
| Price To Earnings Ratio | 29.486 | 40.147 | 51.469 | 74.186 | 89.653 | |
| Price To Earnings Growth Ratio | 0.711 | 1.224 | 0.872 | 1.068 | -1.146 | |
| Forward Price To Earnings Growth Ratio | 0.711 | 1.224 | 0.872 | 1.068 | -1.146 | |
| Price To Earnings Diluted Ratio | 30.370 | 41.489 | 53.344 | 76.564 | 92.576 | |
| Price To Earnings Diluted Growth Ratio | 0.724 | 1.250 | 0.914 | 1.101 | -1.189 | |
| Price To Book Ratio | 4.338 | 5.292 | 5.767 | 6.700 | 5.864 | |
| Price To Sales Ratio | 4.933 | 5.819 | 6.822 | 7.686 | 7.108 | |
| Price To Free Cash Flow Ratio | 18.849 | 24.595 | 35.600 | 35.436 | 34.565 | |
| Price To Operating Cash Flow Ratio | 18.030 | 23.017 | 33.016 | 33.713 | 31.412 | |
| Debt To Assets Ratio | 0.090 | 0.122 | 0.132 | 0.111 | 0.212 | |
| Debt To Equity Ratio | 0.128 | 0.176 | 0.192 | 0.154 | 0.321 | |
| Debt To Capital Ratio | 0.113 | 0.149 | 0.161 | 0.133 | 0.243 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.196 | |
| Financial Leverage Ratio | 1.424 | 1.436 | 1.457 | 1.387 | 1.508 | |
| Working Capital Turnover Ratio | 1.909 | 2.172 | 2.020 | 1.812 | 1.456 | |
| Operating Cash Flow Ratio | 1.053 | 1.173 | 0.595 | 0.631 | 1.044 | |
| Operating Cash Flow Sales Ratio | 0.274 | 0.253 | 0.207 | 0.228 | 0.226 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.957 | 0.936 | 0.927 | 0.951 | 0.909 | |
| Debt Service Coverage Ratio | 0.000 | 3.910 | 1.910 | 1.004 | 4.895 | |
| Interest Coverage Ratio | 0.000 | 4.506 | 54.543 | 35.070 | 3.973 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 2.292 | 2.004 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.885 | 1.308 | 0.910 | 1.291 | 0.582 | |
| Capital Expenditure Coverage Ratio | 23.021 | 15.586 | 13.777 | 20.570 | 10.962 | |
| Dividend Paid And Capex Coverage Ratio | 23.021 | 15.586 | 13.777 | 20.570 | 10.962 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 20.724 | 21.771 | 31.363 | 48.362 | 59.064 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 98.2% | ▼-0.4% | ▼-0.2% |
| Ebit Margin | 22.2% | ▼-3.8% | ▲3.2% |
| Ebitda Margin | 23.3% | ▼-3.9% | ▲3.2% |
| Operating Profit Margin | 21.6% | ▼-2.6% | ▲4.7% |
| Pretax Profit Margin | 24.7% | ▲4.0% | ▲7.4% |
| Continuous Operations Profit Margin | 16.7% | ▲2.2% | ▲4.2% |
| Net Profit Margin | 16.7% | ▲2.2% | ▲4.2% |
| Bottom Line Profit Margin | 16.7% | ▲2.2% | ▲4.2% |
| Current Ratio | 3.393 | ▼-0.004 | ▲0.212 |
| Quick Ratio | 3.301 | ▲0.017 | ▲0.210 |
| Solvency Ratio | 0.369 | ▲0.043 | ▲0.097 |
| Cash Ratio | 0.959 | ▲0.500 | ▲0.224 |
| Price To Earnings Ratio | 29.486 | ▼-10.661 | ▼-27.502 |
| Price To Earnings Growth Ratio | 0.711 | ▼-0.512 | ▲0.165 |
| Forward Price To Earnings Growth Ratio | 0.711 | ▼-0.512 | ▲0.165 |
| Price To Earnings Diluted Ratio | 30.370 | ▼-11.119 | ▼-28.498 |
| Price To Earnings Diluted Growth Ratio | 0.724 | ▼-0.526 | ▲0.164 |
| Price To Book Ratio | 4.338 | ▼-0.954 | ▼-1.254 |
| Price To Sales Ratio | 4.933 | ▼-0.885 | ▼-1.540 |
| Price To Free Cash Flow Ratio | 18.849 | ▼-5.747 | ▼-10.960 |
| Price To Operating Cash Flow Ratio | 18.030 | ▼-4.987 | ▼-9.808 |
| Debt To Assets Ratio | 0.090 | ▼-0.033 | ▼-0.044 |
| Debt To Equity Ratio | 0.128 | ▼-0.048 | ▼-0.066 |
| Debt To Capital Ratio | 0.113 | ▼-0.036 | ▼-0.047 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.039 |
| Financial Leverage Ratio | 1.424 | ▼-0.012 | ▼-0.019 |
| Working Capital Turnover Ratio | 1.909 | ▼-0.262 | ▲0.035 |
| Operating Cash Flow Ratio | 1.053 | ▼-0.120 | ▲0.154 |
| Operating Cash Flow Sales Ratio | 0.274 | ▲0.021 | ▲0.036 |
| Free Cash Flow Operating Cash Flow Ratio | 0.957 | ▲0.021 | ▲0.021 |
| Debt Service Coverage Ratio | 0.000 | ▼-3.910 | ▼-2.344 |
| Interest Coverage Ratio | 0.000 | ▼-4.506 | ▼-19.619 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▼-0.859 |
| Operating Cash Flow Coverage Ratio | 1.885 | ▲0.576 | ▲0.689 |
| Capital Expenditure Coverage Ratio | 23.021 | ▲7.434 | ▲6.237 |
| Dividend Paid And Capex Coverage Ratio | 23.021 | ▲7.434 | ▲6.237 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 20.724 | ▼-1.047 | ▼-15.533 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $14.11B | $13.70B | $12.87B | $11.44B | $8.06B | |
| Enterprise value | $13.81B | $13.93B | $13.05B | $11.44B | $8.16B | |
| EV / Sales | 4.83x | 5.91x | 6.92x | 7.69x | 7.20x | |
| EV / Op. cash flow | 17.65x | 23.39x | 33.47x | 33.71x | 31.80x | |
| EV / Free cash flow | 18.45x | 24.99x | 36.09x | 35.44x | 34.99x | |
| EV / EBITDA | 20.72x | 21.77x | 31.36x | 48.36x | 59.06x | |
| Net debt / EBITDA | -0.45x | 0.35x | 0.43x | 0.00x | 0.72x | |
| Current ratio | 3.39x | 3.40x | 2.45x | 2.70x | 3.96x | |
| Income quality | 1.64x | 1.75x | 1.56x | 2.20x | 2.86x | |
| Graham number | $59 | $44 | $36 | $25 | $18 | |
| Graham net-net | $7 | $3 | $4 | $6 | $2 | |
| Tax burden | 67.8% | 70.2% | 75.2% | 72.2% | 88.4% | |
| Interest burden | 110.8% | 79.3% | 84.1% | 96.8% | 79.7% | |
| Working capital | $1.78B | $1.22B | $952.2M | $915.8M | $727.0M | |
| Invested capital | $2.32B | $1.85B | $1.33B | $1.10B | $882.8M | |
| Return on assets | 10.3% | 9.2% | 7.7% | 6.5% | 4.3% | |
| Operating ROA | 14.8% | 16.4% | 8.9% | 11.2% | 5.4% | |
| Return on tangible assets | 10.3% | 9.3% | 7.8% | 6.6% | 4.3% | |
| Return on equity | 14.7% | 13.2% | 11.2% | 9.0% | 6.5% | |
| Return on invested capital | 10.8% | 12.5% | 6.8% | 9.0% | 5.0% | |
| Return on capital employed | 15.9% | 17.8% | 9.7% | 13.6% | 5.6% | |
| Earnings yield | 3.4% | 2.5% | 1.9% | 1.4% | 1.1% | |
| Free cash flow yield | 5.3% | 4.1% | 2.8% | 2.8% | 2.9% | |
| Capex / Op. cash flow | 4.3% | 6.4% | 7.3% | 4.9% | 9.1% | |
| Capex / Depreciation | 113.0% | 141.0% | 132.9% | 105.8% | 214.7% | |
| Capex / Sales | 1.2% | 1.6% | 1.5% | 1.1% | 2.1% | |
| SG&A / Sales | 40.4% | 42.8% | 47.0% | 50.6% | 51.5% | |
| R&D / Sales | 35.5% | 31.0% | 29.9% | 31.2% | 28.9% | |
| Stock comp / Sales | 7.6% | 8.3% | 10.3% | 11.6% | 11.8% | |
| Intangibles / Total assets | 0.0% | 1.0% | 1.1% | 1.6% | 0.0% | |
| Days sales outstanding | 88d | 74d | 85d | 86d | 60d | |
| Days payables outstanding | 735d | 1072d | 1226d | 1059d | 1315d | |
| Operating cycle | 571d | 690d | 437d | 638d | 838d | |
| Cash conversion cycle | -164d | -382d | -788d | -421d | -476d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-16 Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showed growth and bone-age monitoring in childhood; puberty and reproductive health concerns through adolescence and young adulthood; and increasingly diverse clinical needs in adulthood, while treatment and self-management demands persisted across life stages The analysis captured impacts beyond traditional medical complications, including daily activities, school, work, caregiving, self-management, and access to care Mapping patient experiences over time may help healthcare professionals anticipate evolving needs and inform education, support strategies, and coordination across care teams SAN DIEGO, Oct. 16, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve throughout a patient''s life. The findings will be presented at the Endocrine Nurses Society Annual Symposium 2026, taking place Oct. 16-17 in Phoenix.
- 2026-10-14 Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-10-13 NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-10-13 Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-10-13 Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX) Amneal Pharmaceuticals (NASDAQ: AMRX - Get Free Report) and Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation. Analyst Ratings This is a breakdown of recent
- 2026-10-12 Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
- 2026-10-09 4 CNS Drug Stocks Worth Watching This World Mental Health Day AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
- 2026-10-06 Here Are Tuesday’s Top Wall Street Analyst Research Calls: Borg Warner, Boyd Gaming, JetBlue, Lattice Semiconductor, Lockheed Martin, Nike, Northrop Grumman, Procter & Gamble, SPX Technologies, and More Pre-Market Stock Futures: Futures are trading higher after we started off the first full trading week of the undefined quarter in solid style, as all major indices finished the day higher despite interest rates continuing to tick higher. Technology led the way, and the tech-heavy Nasdaq responded, closing at 27,477, up 1.05% to a new
- 2026-09-30 Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will capture caregiver-reported information to better understand the experience and burden of caring for someone with Prader-Willi syndrome Integrated analysis will further evaluate adverse events of special interest — including fluid retention, hyperglycemia, hirsutism and hypertrichosis — during VYKAT XR treatment SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in Philadelphia.
- 2026-09-28 Neurocrine Biosciences Appoints Eiry W. Roberts, M.D. SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.